Dos Santos Ariolana A, Carvalho Adriana A
Ariolana A dos Santos, Adriana A Carvalho, Department of Pharmacy, Federal University of Sergipe, Campus Lagarto, 49400-00 Lagarto, Sergipe, Brazil.
World J Gastroenterol. 2015 Jan 7;21(1):139-54. doi: 10.3748/wjg.v21.i1.139.
The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.
幽门螺杆菌(H. pylori)感染的最佳治疗方法应兼具高治愈率、短疗程、良好的副作用谱以及低成本。为提高幽门螺杆菌根除率,人们提出了多种策略,包括将治疗疗程延长至14天、采用四联疗法(四重、序贯和联合治疗)以及使用新型抗生素,如左氧氟沙星。然而,三联疗法在巴西、美国以及整个欧洲仍是最广泛接受的一线治疗方案。由于该疗法受克拉霉素耐药性的限制,全球范围内已对其他治疗方案进行了研究。这篇综述描述了目前直接比较这些不同疗法及其疗效的研究文献。